PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Owlstone Medical’s breath biopsy test improves detection of liver disease

Cambridge-based Owlstone Medical has announced new results from a study of its breath-based diagnostic test for liver disease, including Nonalcoholic Fatty Liver Disease (NAFLD) and associated Nonalcoholic steatohepatitis (NASH).

The study investigated the use of exhaled limonene as a breath biomarker to measure liver function and stage liver disease in 32 cirrhosis and 12 cirrhotic hepatocellular-carcinoma patients, compared with 40 in the control group.

The breath samples from each group were analysed by Owlstone’s breath biopsy platform, resulting in positive results (73% sensitivity and 77% specificity) demonstrating the efficacy of using limonene levels to find alterations in liver function.

According to Owlstone, these results have promise, showing that limonene could be used as a marker of liver metabolic capacity.

“This study represents a major milestone for Owlstone Medical, as it is the first proof of the value of our EVOC probe approach for the development of breath tests in areas of high clinical need,” said Billy Boyle, co-founder and chief executive officer at Owlstone.

“Much like how PET scans work, this involves the introduction of a compound to the body that elicits a strong and clearly readable signal over background.

“We have identified a number of additional highly promising compounds that we are working to validate as EVOC probes for liver disease and we believe our EVOC probe approach can be applied to other disease areas, including lung cancer, where earlier and improved diagnosis is clearly needed to save lives,” he added.

Owlstone is currently developing a number of non-invasive quantitative breath tests that use its proprietary EVOC Probes, including limonene along with inflammatory exhaled biomarkers, to measure liver enzyme activity and provide information on the health of the liver and for NAFLD/NASH diagnosis and prognosis.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026